Regulatory role of CARD3 in left ventricular remodelling and dysfunction after myocardial infarction
Liangpeng Li1, Xiaodi Wang1, Wen Chen1
1Department of Thoracic and Cardiovascular Surgery, Nanjing Hospital Affiliated to Nanjing Medical University, Changle Road 68, Nanjing, 210006, Jiangsu, People's Republic of China.
Insights
Caspase activation and recruitment domain 3 (CARD3) exacerbates cardiac remodeling after myocardial infarction (MI). Inhibiting CARD3 protects the heart, reducing infarct size and improving function by modulating NF-κB and p38 signaling.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Cell Death Research
Background:
- Caspase activation and recruitment domain 3 (CARD3) is a kinase involved in apoptosis and tissue development.
- The role of CARD3 in myocardial infarction (MI) and cardiac remodeling is not well understood.
Purpose of the Study:
- To investigate the functional significance of CARD3 in cardiac remodeling post-MI.
- To elucidate the underlying molecular mechanisms of CARD3's effects on the heart after infarction.
Main Methods:
- Analysis of CARD3 expression in human and mouse post-MI hearts.
- Generation and MI induction in CARD3-knockout (KO) and CARD3-overexpressing mice.
- Assessment of cardiac function, infarct size, apoptosis, inflammation, hypertrophy, and fibrosis.
- In vitro studies using neonatal rat cardiomyocytes exposed to hypoxia.
Main Results:
- CARD3 expression is upregulated in failing hearts post-MI.
- CARD3-KO mice showed reduced infarct size, improved survival, preserved left ventricle (LV) function, less cardiomyocyte apoptosis, and attenuated LV remodeling compared to wild-type mice.
- CARD3 overexpression led to opposite effects, worsening MI outcomes.
- CARD3-mediated detrimental effects involved activation of NF-κB and p38 signaling pathways.
Conclusions:
- CARD3 is a novel positive modulator of cardiac remodeling after MI.
- CARD3 promotes adverse ventricular remodeling through NF-κB and p38 signaling activation.
- Targeting CARD3 may offer a therapeutic strategy for treating heart failure post-MI.
Abstract:
Caspase activation and recruitment domain 3 (CARD3) is a caspase recruitment domain (CARD)-containing serine/threonine kinase and plays a pivotal role in apoptosis, immunity, tissue development and proliferation. To date, the causal relationship between CARD3 and myocardial infarction (MI) remains largely unexplored. This study aimed to identify the functional significance of CARD3 in the regulation of cardiac remodelling after MI and the underlying mechanisms of its effects. The levels of CARD3 expression were up-regulated in failing human and mouse post-infarction hearts. In addition, CARD3-knockout (KO) mice and transgenic mice overexpressing CARD3 in the heart were then generated and subjected to MI. Compared with wild-type (WT) control mice, CARD3-KO mice developed smaller infarct sizes, improved survival rates, and preserved left ventricle (LV) function after MI. Significantly, CARD3-KO hearts had less cardiomyocyte apoptosis and inflammatory cell infiltration in the infarct border zone. Attenuated LV remodelling was also observed in the KO hearts following MI, with reduced cardiac hypertrophy and fibrosis. Conversely, CARD3 overexpression resulted in the opposite MI-induced phenotype. Similar results were observed in ex vivo-cultured neonatal rat cardiomyocytes exposed to hypoxia. Mechanistically, we discovered that the CARD3-mediated detrimental effects of MI were associated with the activation of the NF-κB and p38 signalling cascades. Taken together, these data demonstrate that CARD3 serves as a novel positive modulator of ventricular remodelling after MI via the regulation of the NF-κB and p38 signalling. Thus, CARD3 may be a promising therapeutic target for the treatment of heart failure after MI.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis III: Medical Management


